BNP Paribas Financial Markets’s Gyre Therapeutics GYRE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $23K | Buy |
3,486
+915
| +36% | +$6.23K | ﹤0.01% | 5210 |
|
|
2026
Q1 | $17.9K | Buy |
2,571
+20
| +0.8% | +$155 | ﹤0.01% | 5113 |
|
|
2025
Q4 | $18K | Buy |
2,551
+388
| +18% | +$2.99K | ﹤0.01% | 5048 |
|
|
2025
Q3 | $16.1K | Buy |
2,163
+867
| +67% | +$6.58K | ﹤0.01% | 4935 |
|
|
2025
Q2 | $9.53K | Buy |
1,296
+801
| +162% | +$6.99K | ﹤0.01% | 4851 |
|
|
2025
Q1 | $3.82K | Sell |
495
-899
| -64% | -$9.86K | ﹤0.01% | 4895 |
|
|
2024
Q4 | $16.9K | Sell |
1,394
-553
| -28% | -$7.08K | ﹤0.01% | 4754 |
|
|
2024
Q3 | $24.4K | Buy |
1,947
+1,427
| +274% | +$18.4K | ﹤0.01% | 3729 |
|
|
2024
Q2 | $6.2K | Sell |
520
-198
| -28% | -$2.72K | ﹤0.01% | 3756 |
|
|
2024
Q1 | $12.6K | Buy |
+718
| New | +$12.9K | ﹤0.01% | 3676 |
|
|
2023
Q4 | – | Sell |
-18
| Closed | -$134 | – | 4039 |
|
|
2023
Q3 | $134 | Hold |
18
| – | – | ﹤0.01% | 3837 |
|
|
2023
Q2 | $97 | Hold |
18
| – | – | ﹤0.01% | 3860 |
|
|
2023
Q1 | $57 | Sell |
18
-19
| -51% | -$72 | ﹤0.01% | 3792 |
|
|
2022
Q4 | $146 | Sell |
37
-6
| -14% | -$24 | ﹤0.01% | 3936 |
|
|
2022
Q3 | $162 | Hold |
43
| – | – | ﹤0.01% | 4623 |
|
|
2022
Q2 | $571 | Sell |
43
-6
| -12% | -$40 | ﹤0.01% | 3943 |
|
|
2022
Q1 | $243 | Sell |
49
-13
| -21% | -$64 | ﹤0.01% | 4076 |
|
|
2021
Q4 | $424 | Sell |
62
-10
| -14% | -$171 | ﹤0.01% | 4121 |
|
|
2021
Q3 | $2.21K | Buy |
72
+6
| +9% | +$197 | ﹤0.01% | 3788 |
|
|
2021
Q2 | $2.13K | Sell |
66
-1,584
| -96% | -$54.4K | ﹤0.01% | 3879 |
|
|
2021
Q1 | $62.4K | Buy |
1,650
+1,132
| +219% | +$51.7K | ﹤0.01% | 3534 |
|
|
2020
Q4 | $24.5K | Sell |
518
-139
| -21% | -$6.02K | ﹤0.01% | 3802 |
|
|
2020
Q3 | $21.2K | Buy |
657
+570
| +655% | +$22.3K | ﹤0.01% | 3818 |
|
|
2020
Q2 | $3.83K | Buy |
87
+79
| +988% | +$3.71K | ﹤0.01% | 4095 |
|
|
2020
Q1 | $275 | Hold |
8
| – | – | ﹤0.01% | 4166 |
|
|
2019
Q4 | $429 | Sell |
8
-181
| -96% | -$7.58K | ﹤0.01% | 4261 |
|
|
2019
Q3 | $6.96K | Hold |
189
| – | – | ﹤0.01% | 4220 |
|
|
2019
Q2 | $10.4K | Sell |
189
-148
| -44% | -$9.25K | ﹤0.01% | 4092 |
|
|
2019
Q1 | $20.5K | Buy |
337
+254
| +306% | +$16.3K | ﹤0.01% | 3905 |
|
|
2018
Q4 | $4.89K | Buy |
83
+31
| +60% | +$2.29K | ﹤0.01% | 3595 |
|
|
2018
Q3 | $4.19K | Hold |
52
| – | – | ﹤0.01% | 4123 |
|
|
2018
Q2 | $4.58K | Buy |
+52
| New | +$9.12K | ﹤0.01% | 4123 |
|
|
2014
Q4 | – | Sell |
-4
| Closed | -$8.26K | – | 2502 |
|
|
2014
Q3 | $8.26K | Buy |
4
+3
| +300% | +$7.42K | ﹤0.01% | 3674 |
|
|
2014
Q2 | $3.31K | Sell |
1
-1
| -50% | -$3.26K | ﹤0.01% | 2827 |
|
|
2014
Q1 | $6.18K | Hold |
2
| – | – | ﹤0.01% | 2373 |
|
|
2013
Q4 | $5.65K | Buy |
+2
| New | +$7.88K | ﹤0.01% | 3020 |
|
|
2013
Q3 | – | Sell |
-15
| Closed | -$49.4K | – | 2630 |
|
|
2013
Q2 | $49.4K | Buy |
+15
| New | +$57.1K | ﹤0.01% | 2670 |
|
Other funds holding GYRE
HH
OCA
VCM
SS
VFT
BNP Paribas Financial Markets's GYRE Position: Q2 2026 in Review
BNP Paribas Financial Markets increased its Gyre Therapeutics (GYRE) stake by 36% in Q2 2026, buying an estimated $6.23K and bringing the position to 3,486 shares worth $23K. The position accounts for ﹤0.01% of the portfolio, ranked #5210.
BNP Paribas Financial Markets first reported a position in GYRE in Q2 2013 and has held it in 37 quarters since. The position peaked at $62.4K in Q1 2021. 56 funds tracked by Wall St. Rank hold GYRE as of Q2 2026.
- BNP Paribas Financial Markets held 3,486 shares of Gyre Therapeutics worth $23K as of Q2 2026.
- BNP Paribas Financial Markets bought 915 Gyre Therapeutics shares in Q2 2026, an estimated $6.23K.
- Gyre Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #5210 holding.
- BNP Paribas Financial Markets first reported a position in Gyre Therapeutics in Q2 2013 and has held it in 37 quarters since.
- BNP Paribas Financial Markets's Gyre Therapeutics position peaked at $62.4K in Q1 2021.
- 56 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2026.
Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.